WO2012103576A1 - Tissue mass indicator determination - Google Patents
Tissue mass indicator determination Download PDFInfo
- Publication number
- WO2012103576A1 WO2012103576A1 PCT/AU2012/000075 AU2012000075W WO2012103576A1 WO 2012103576 A1 WO2012103576 A1 WO 2012103576A1 AU 2012000075 W AU2012000075 W AU 2012000075W WO 2012103576 A1 WO2012103576 A1 WO 2012103576A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- impedance
- determining
- value
- tissue mass
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0537—Measuring body composition by impedance, e.g. tissue hydration or fat content
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/45—For evaluating or diagnosing the musculoskeletal system or teeth
- A61B5/4519—Muscles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4869—Determining body composition
- A61B5/4872—Body fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6824—Arm or wrist
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6825—Hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6828—Leg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6829—Foot or ankle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7225—Details of analog processing, e.g. isolation amplifier, gain or sensitivity adjustment, filtering, baseline or drift compensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7278—Artificial waveform generation or derivation, e.g. synthesising signals from measured signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
- A61B5/743—Displaying an image simultaneously with additional graphical information, e.g. symbols, charts, function plots
Definitions
- the present invention relates to a method and apparatus for use in determining a tissue mass indicator indicative of a lean tissue mass, and which in one example can be used to identify changes in tissue mass.
- lean tissue mass LTM
- SCI spinal cord injury
- DEXA Dual Energy X-ray Absortiometry
- X-ray absorption scanning of a subject to determine attenuation of transmitted X-rays, which in turn allows information regarding the subject's body composition to be determined.
- DEXA can be used to determine a subject's bone mineral density, also known as the subject's ash weight.
- additional information such as the subject's weight and intra- and extracellular fluid levels, this can be used to derive a subject's fat mass and fat-free mass.
- bioelectrical impedance This involves measuring the electrical impedance of a subject's body using a series of electrodes placed on the skin surface. Changes in electrical impedance at the body's surface are used to determine parameters, such as changes in fluid levels, associated with the cardiac cycle or oedema, or other conditions which affect body habitus.
- WO00/79255 describes a method of detection of oedema by measuring bioelectrical impedance at two different anatomical regions in the same subject at a single low frequency alternating current. The two measurements are analysed to obtain an indication of the presence of tissue oedema by comparing with data obtained from a normal population.
- WO2005/122888 describes a method of detecting tissue oedema in a subject.
- the method includes determining a measured impedance for first and second body segments.
- An index indicative of a ratio of the extra-cellular to intra-cellular fluid is then calculated for each body segment, with these being used to determine an index ratio based on the index for the first and second body segments.
- the index ratio can in turn be used to determine the presence, absence or degree of tissue oedema, for example by comparing the index ratio to a reference or previously determined index ratios.
- WO2008/138602 describes a method for use in analysing impedance measurements performed on a subject, the method including, in a processing system determining at least one impedance value, representing the impedance of at least a segment of the subject, determining an indicator indicative of a subject parameter using the at least one impedance value and a reference and displaying a representation of the indicator.
- the present invention provides a method of determining a measure of lean tissue mass for a segment of a subject, the method including, in a processing system: a) determining at least one impedance value at at least one frequency, the at least one impedance value representing the impedance of the segment; b) determining a tissue mass impedance parameter value using the at least one impedance value; and,
- tissue mass impedance parameter value is indicative of an intracellular resistance.
- the method includes:
- the at least one fluid level impedance parameter value is indicative of intracellular and extracellular fluid levels.
- the fluid level indicator is determined based on a ratio of intracellular to extracellular resistance.
- the method includes determining an intracellular resistance using the formula:
- the method includes:
- c) in the processing system determining at least one of the tissue mass indicator and a fluid level indicator using the first and second impedance parameter values.
- the method includes, in the processing system, determining the tissue mass indicator using the equation: Ind sf( n - Rn ) wherein: Ind is the tissue mass indicator
- R ( y is a first impedance parameter value
- Ri2 is a second impedance parameter value
- the method includes, in the processing system, determining the tissue mass indicator using the equation:
- the constant C has a value between 10 and 15, and the scaling factor sf ' has a value of between 0.002 and 0.004.
- the constant C has a value of 13.3, and the scaling factor has a value of 0.0033.
- At least one of a constant and a scaling factor are determined from a reference population selected based on at least one of:
- the method includes determining at least two impedance values including:
- the first impedance value is indicative of the parameter value Ro and wherein the second impedance value is indicative of the parameter value R ⁇ .
- the method includes:
- the method includes determining impedance parameter values by at least one of: a) estimating values based on impedance measurements performed at selected respective frequencies;
- the method includes displaying a representation of at least one of the tissue mass indicator and a fluid level indicator.
- the method includes in the processing system, causing one or more impedance measurements to be performed.
- the method includes, in the processing system:
- the method includes, in the processing system:
- the method includes: a) determining a number of impedance measurements, the number of impedance measurements including at least one impedance measurement at each of a number of measurement frequencies; and,
- the present invention provides apparatus for use in analysing impedance measurements performed on a subject, the apparatus including a processing system for:
- the apparatus includes:
- a signal generator for applying one or more electrical signals to the subject using a first set of electrodes
- controller includes the processing system.
- the processing system includes the controller. It will be appreciated that the broad forms of the invention can be used in conjunction, and can be used in a wide range of applications, such as monitoring changes in tissue mass during training, rehabilitation and changes in nutrition. Brief Description of the Drawings
- Figure 1 is a schematic of an example of impedance determination apparatus
- Figure 2 is a flowchart of an example of a process for determining a tissue mass indicator
- Figure 3 A is a schematic of an example of a theoretical equivalent circuit for biological tissue
- Figure 3 B is an example of a locus of impedance known as a Wessel plot
- Figure 3C is a graph of an example of changes in tissue mass indicator over time
- Figure 3D is a graph of an example of changes in fluid level indicator over time
- Figure 4 is a flowchart of an example of a process for determining an indicator determining a tissue mass indicator
- Figures 5A and 5B are diagrams of examples of electrode positions for use in measuring limb impedances
- Figures 5C and 5D are schematic diagrams of examples of electrode positions for use in measuring limb impedances
- Figure 5E is a schematic diagram of an example of electrode positions for use in measuring a calf impedance
- Figure 6A to 6C are schematic diagrams of first examples of representations of indicators
- Figure 7 is a graph of an example of the relationship between the impedance parameter value Ri and lean tissue mass measured using DXA.
- the apparatus includes a measuring device 100 including a processing system 102, connected to one or more signal generators 1 17A, 1 17B, via respective first leads 123 A, 123B, and to one or more sensors 1 18A, 1 18B, via respective second leads 125A, 125B.
- the connection may be via a switching device, such as a multiplexer, although this is not essential.
- the signal generators 1 17A, U7B are coupled to two first electrodes 1 13A, 1 13B, which therefore act as drive electrodes to allow signals to be applied to the subject S, whilst the one or more sensors 1 18A, 1 18B are coupled to the second electrodes 1 15 A, 1 15B, which act as sense electrodes, allowing signals across the subject S to be sensed.
- the signal generators 1 17A, 117B and the sensors 1 18A, 1 18B may be provided at any position between the processing system 102 and the electrodes 1 13 A, 1 13B, 1 15 A, 1 15B, and may be integrated into the measuring device 100.
- the signal generators 1 17A, 1 17B and the sensors 1 18A, 1 18B are integrated into an electrode system, or another unit provided near the subject S, with the leads 123A, 123B, 125 A, 125B connecting the signal generators 1 17A, 1 17B and the sensors 1 18 A, 1 18B to the processing system 102.
- the above described system is a two channel device, used to perform a classical four-terminal impedance measurement, with each channel being designated by the suffixes A, B respectively.
- the use of a two channel device is for the purpose of example only, and multiple channel devices can alternatively be used to allow multiple body segments to be measured without requiring reattachment of electrodes.
- An example of such a device is described in copending patent application number WO2009059351.
- An optional external interface 103 can be used to couple the measuring device 100, via wired, wireless or network connections, to one or more peripheral devices 104, such as an external database or computer system, barcode scanner, or the like.
- the processing system 102 will also typically include an I/O device 105, which may be of any suitable form such as a touch screen, a keypad and display, or the like.
- the processing system 102 is adapted to generate control signals, which cause the signal generators 1 17A, 1 17B to generate one or more alternating signals, such as voltage or current signals of an appropriate waveform, which can be applied to a subject S, via the first electrodes 1 13A, 1 13B.
- the sensors 1 18A, 1 18B then determine the voltage across or current through the subject S, using the second electrodes 1 15A, 1 15B and transfer appropriate signals to the processing system 102.
- the processing system 102 may be any form of processing system which is suitable for generating appropriate control signals and at least partially interpreting the measured signals to thereby determine the subject's bioelectrical impedance, and optionally determine other information such as relative fluid levels, or the presence, absence or degree of conditions, such as oedema, lymphoedema, measures of body composition, cardiac function, or the like.
- the processing system 102 may therefore be a suitably programmed computer system, such as a laptop, desktop, PDA, smart phone or the like.
- the processing system 102 may be formed from specialised hardware, such as an FPGA (field programmable gate array), or a combination of a programmed computer system and specialised hardware, or the like.
- the first electrodes 1 13 A, 1 13B are positioned on the subject to allow one or more signals to be injected into the subject S.
- the location of the first electrodes will depend on the segment of the subject S under study.
- the first electrodes 1 13 A, 1 13B can be placed on the thoracic and neck region of the subject S to allow the impedance of the chest cavity to be determined.
- positioning electrodes on the wrist and ankles of a subject allows the impedance of limbs, torso and/or the entire body to be determined.
- one or more alternating signals are applied to the subject S, via the first leads 123 A, 123B and the first electrodes 1 13A, 1 13B.
- the nature of the alternating signal will vary depending on the nature of the measuring device and the subsequent analysis being performed.
- the system can use Bioimpedance Analysis (BIA) in which a single low frequency signal is injected into the subject S, with the measured impedance being used directly in the determination of biological parameters.
- the applied signal has a relatively low frequency, such as below 100 kHz, more typically below 50 kHz and more preferably below 10 kHz.
- such low frequency signals can be used as an estimate of the impedance at zero applied frequency, commonly referred to as the impedance parameter value RQ, which is in turn indicative of extracellular fluid levels.
- the applied signal can have a relatively high frequency, such as above 200 kHz, and more typically above 500 kHz, or 1000 kHz.
- such high frequency signals can be used as an estimate of the impedance at infinite applied frequency, commonly referred to as the impedance parameter value R ⁇ , which is in turn indicative of a combination of the extracellular and intracellular fluid levels, as will be described in more detail below.
- the system can use Bioimpedance Spectroscopy (BIS) in which impedance measurements are performed at each of a number of frequencies ranging from very low frequencies (4 kHz) to higher frequencies (1000 kHz), and can use as many as 256 or more different frequencies within this range.
- BIOS Bioimpedance Spectroscopy
- Such measurements can be performed by applying a signal which is a superposition of plurality of frequencies simultaneously, or a number of alternating signals at different frequencies sequentially, depending on the preferred implementation.
- the frequency or frequency range of the applied signals may also depend on the analysis being performed.
- impedance parameter values such as values of Ro, Z c , R ⁇ , which correspond to the impedance at zero, characteristic and infinite frequencies. These can in turn be used to determine information regarding both intracellular and extracellular fluid levels, as will be described in more detail below.
- a further alternative is for the system to use Multiple Frequency Bioimpedance Analysis (MFBIA) in which multiple signals, each having a respective frequency are injected into the subject S, with the measured impedances being used in the assessment of fluid levels.
- MFBIA Multiple Frequency Bioimpedance Analysis
- four frequencies can be used, with the resulting impedance measurements at each frequency being used to derive impedance parameter values, for example by fitting the measured impedance values to a Cole model, as will be described in more detail below.
- the impedance measurements at each frequency may be used individually or in combination.
- the measuring device 100 may either apply an alternating signal at a single frequency, at a plurality of frequencies simultaneously, or a number of alternating signals at different frequencies sequentially, depending on the preferred implementation.
- the frequency or frequency range of the applied signals may also depend on the analysis being performed.
- the applied signal is generated by a voltage generator, which applies an alternating voltage to the subject 5, although alternatively current signals may be applied.
- the voltage source is typically symmetrically arranged, with each of the signal generators 1 17A, 1 17B being independently controllable, to allow the signal voltage across the subject to be varied.
- a voltage difference and/or current is measured between the second electrodes 1 15A, 1 15B.
- the voltage is measured differentially, meaning that each sensor 1 18A, 1 18B is used to measure the voltage at each second electrode 1 15 A, 1 15B and therefore need only measure half of the voltage as compared to a single ended system.
- the acquired signal and the measured signal will be a superposition of voltages generated by the human body, such as the ECG (electrocardiogram), voltages generated by the applied signal, and other signals caused by environmental electromagnetic interference. Accordingly, filtering or other suitable analysis may be employed to remove unwanted components.
- ECG electrocardiogram
- filtering or other suitable analysis may be employed to remove unwanted components.
- the acquired signal is typically demodulated to obtain the impedance of the system at the applied frequencies.
- One suitable method for demodulation of superposed frequencies is to use a Fast Fourier Transform (FFT) algorithm to transform the time domain data to the frequency domain. This is typically used when the applied current signal is a superposition of applied frequencies.
- FFT Fast Fourier Transform
- Another technique not requiring windowing of the measured signal is a sliding window FFT.
- the applied current signals are formed from a sweep of different frequencies
- a signal processing technique such as multiplying the measured signal with a reference sine wave and cosine wave derived from the signal generator, or with measured sine and cosine waves, and integrating over a whole number of cycles.
- This process known variously as quadrature demodulation or synchronous detection, rejects all uncorrected or asynchronous signals and significantly reduces random noise.
- Other suitable digital and analogue demodulation techniques will be known to persons skilled in the field.
- impedance or admittance measurements are determined from the signals at each frequency by comparing the recorded voltage and the current through the subject.
- the demodulation algorithm can then produce amplitude and phase signals at each frequency, allowing an impedance value at each frequency to be determined.
- the distance between the second electrodes 1 15A, 1 15B may be measured and recorded.
- other parameters relating to the subject may be recorded, such as the height, weight, age, sex, health status, any interventions and the date and time on which they occurred.
- Other information, such as current medication, may also be recorded. This can then be used in performing further analysis of the impedance measurements, so as to allow determination of the presence, absence or degree of oedema, to assess body composition, or the like.
- the accuracy of the measurement of impedance can be subject to a number of external factors. These can include, for example, the effect of capacitive coupling between the subject and the surrounding environment, the leads and the subject, the electrodes, or the like, which will vary based on factors such as lead construction, lead configuration, subject position, or the like. Additionally, there are typically variations in the impedance of the electrical connection between the electrode surface and the skin (known as the "electrode impedance"), which can depend on factors such as skin moisture levels, melatonin levels, or the like. A further source of error is the presence of inductive coupling between different electrical conductors within the leads, or between the leads themselves.
- a reference voltage within the subject S which is equal to a reference voltage of the measurement apparatus, will be close to the effective body centre of the subject, as considered relative to the electrode placement.
- the measuring device reference voltage is typically ground, this results in the body centre of the subject S being as close to ground as possible, which minimises the overall signal magnitude across the subject's torso, thereby minimising stray currents.
- a symmetrical voltage about the sensing electrodes can be achieved by using a symmetrical voltage source, such as a differential bidirectional voltage drive scheme, which applies a symmetrical voltage to each of the drive electrodes 1 13 A, 1 13B.
- a symmetrical voltage source such as a differential bidirectional voltage drive scheme
- this is not always effective if the contact impedances for the two drive electrodes 1 13 A, 1 13B are unmatched, or if the impedance of the subject S varies along the length of the subject S, which is typical in a practical environment.
- the apparatus overcomes this by adjusting the differential voltage drive signals applied to each of the drive electrodes 1 13A, 1 13B, to compensate for the different electrode impedances, and thereby restore the desired symmetry of the voltages across the subject S.
- This process is referred to herein as balancing and in one example, helps reduce the magnitude of the common mode signal, and hence reduce current losses caused by parasitic capacitances associated with the subject.
- the degree of imbalance and hence the amount of balancing required, can be determined by monitoring the signals at the sense electrodes 1 15A, 1 15B, and then using these signals to control the signal applied to the subject via the drive electrodes 1 13 A, 1 13B.
- the degree of imbalance can be calculated by determining an additive voltage from the voltages detected at the sense electrodes 1 15 A, 1 15B.
- the voltages sensed at each of the sense electrodes 1 15A, 1 15B are used to calculate a first voltage, which is achieved by combining or adding the measured voltages.
- the first voltage can be an additive voltage (commonly referred to as a common mode voltage or signal) which can be determined using a differential amplifier.
- a differential amplifier is typically used to combine two sensed voltage signals V a> Vb, to determine a second voltage, which in one example is a voltage differential V a -Vb across the points of interest on the subject S.
- the voltage differential is used in conjunction with a measurement of the current flow through the subject to derive impedance values.
- differential amplifiers typically also provide a "common mode" signal ( V a + Vb)/2, which is a measure of the common mode signal.
- differential amplifiers Whilst differential amplifiers include a common mode rejection capability, this is generally of only finite effect and typically reduces in effectiveness at higher frequencies, so a large common mode signal will produce an error signal superimposed on the differential signal.
- the error caused by common mode signals can be minimised by calibration of each sensing channel.
- the common mode error will be zero.
- the two sensing channels of the differential amplifier are digitised before differential processing. It is therefore straightforward to apply calibration factors independently to each channel to allow the characteristics to be matched to a high degree of accuracy, thereby achieving a low common mode error.
- the applied voltage signals can be adjusted, for example by adjusting the relative magnitude and/or phase of the applied signals, to thereby minimise the common mode signal and substantially eliminate any imbalance.
- An example of this process is described in more detail in copending patent application number WO2009059351.
- An example of the operation of the apparatus in analysing impedance measurements will now be described with reference to Figure 2.
- the processing system 102 causes a current signal to be applied to the subject S, with the induced voltage across the subject S being measured, with signals representing the measured voltage and the applied current being returned to the processing system 102 for analysis.
- tissue mass indicator When the process is being used to determine a tissue mass indicator, this is typically performed for at least a segment of the subject 5 that is suspected of being susceptible to tissue mass loss. This can include any large muscle group, such as the subject's back, legs, thigh, calf or the like.
- measured voltage and current signals are used by the processing system 102 to determine at least one impedance value at at least one frequency, the at least one impedance value representing the impedance of a segment of the subject.
- the at least one impedance value is used by the processing system 102, to determine a tissue mass impedance parameter value.
- the nature of the tissue mass impedance parameter value can vary, but in general this represents an intracellular impedance Rj, which depends on the amount of intracellular fluid, and hence the amount of lean tissue present.
- Figure 3A is an example of an equivalent circuit that effectively models the electrical behaviour of biological tissue.
- the equivalent circuit has two branches that represent current flow through extracellular fluid and intracellular fluid, respectively.
- the extracellular fluid component of biological impedance is represented by an extracellular resistance R e
- the intracellular fluid component is represented by an intracellular resistance Rt and a capacitance C representative of the cell membranes.
- the relative magnitudes of the extracellular and intracellular components of impedance of an alternating current (AC) are frequency dependent.
- AC alternating current
- the capacitor acts as a perfect insulator and all current flows through the extracellular fluid, hence the resistance at zero frequency, Ro, equals the extracellular resistance R e .
- the capacitor acts as a perfect conductor and the current passes through the parallel resistive combination.
- r is the time constant of the capacitive circuit.
- impedance parameters X c , Ro, R ⁇ , Z c or a may be determined in any one of a number of manners such as by:
- the Wessel plot is often used in BIS devices, which perform multiple measurements over a range of frequencies, such as from 4 kHz to 1000 kHz, using 256 or more different frequencies within this range.
- a regression procedure is then used to fit the measured data to the theoretical semi-circular locus, allowing values for X c , Ro, R ⁇ , Z c or a to be calculated.
- Such a regression analysis is computationally expensive, typically requiring a larger or more expensive device.
- the regression analysis and also requires a large number of data points, which can cause the measurement process to take a significant amount of time.
- a circle fitting technique can be used in which only three measurement points are required.
- three simultaneous equations representing the geometric relationships between points on a circle are solved to allow calculation of the radius (r) and the co-ordinates of the centre of the circle (i, j) as the three parameters which define the circle.
- X c , Ro, R ⁇ , Z c or a are readily computed from geometric first principles.
- This circle technique allows a value for X c , Ro, R ⁇ , Z c or a to be derived in a computationally less expensive manner than if a regression analysis is performed, and requires a reduced number of data points allowing a more rapid measurement process.
- impedance measurements are performed at more than three frequencies, with circle parameters for all possible combinations of impedance measurements at three frequencies being calculated. The average can be provided along with the standard deviation as a measure of the goodness of fit of the data to the Cole model.
- one of the measurements is inaccurate, this can be accounted for by excluding one or more outlier measurements, such as measurements that deviates the greatest amount from the mean, or measurements differing by more than a set number of standard deviations from the mean, allowing the mean to be recalculated, thereby providing more accurate values. Whilst this process uses additional measurements, such as four or five measurements, this is still significantly less than the 256 or more frequencies typically performed using a BIS measurement protocol, allowing the measurement process to be performed more quickly.
- one or more outlier measurements such as measurements that deviates the greatest amount from the mean, or measurements differing by more than a set number of standard deviations from the mean, allowing the mean to be recalculated, thereby providing more accurate values. Whilst this process uses additional measurements, such as four or five measurements, this is still significantly less than the 256 or more frequencies typically performed using a BIS measurement protocol, allowing the measurement process to be performed more quickly.
- the frequencies used are in the range 0 kHz to 1000 kHz, and in one specific example, four measurements are recorded at frequencies of 25 kHz, 50 kHz, 100 kHz, and 200 kHz, although any suitable measurement frequencies can be used.
- a further alternative for determining impedance parameter values such as X c , Ro, R ⁇ , Z c or a is to perform impedance measurements at a single frequency, and use these as an estimate of the parameter values.
- measurements performed at a single low frequency typically less than 50 kHz
- measurements at a single high frequency typically more than 100 kHz
- R ⁇ allowing a value of Rj to be determined using equation (2) above.
- the above described equivalent circuit models the resistivity as a constant value and does not therefore accurately reflect the impedance response of a subject, and in particular does not accurately model the change in orientation of the erythrocytes in the subject's blood stream, or other relaxation effects.
- an improved CPE based model may alternatively be used.
- the tissue mass impedance parameter value can be used to determine a tissue mass indicator.
- the tissue mass indicator is in the form of a numerical value which can be used to determine a relative level of lean tissue mass, and accordingly, in one form, the tissue mass indicator is simply the numerical value of the intracellular resistance R,.
- a single reading can be scaled, for example based on a scaling factor determined from a study of a reference population.
- DXA alternative technique
- a regression analysis can then be performed to determine a relationship between the LTM and R,.
- the regression analysis provides a relationship of the form;
- the method includes determining first and second tissue mass impedance parameter values and then determining the tissue mass indicator using the first and second respective tissue mass impedance parameter values.
- the first and second tissue mass impedance parameter values are typically determined for the same body segment, but at different times, thereby allowing a longitudinal analysis to be performed. It will be appreciated that this is particularly useful in monitoring changes in the tissue mass over time, which can be used to determine the degree of tissue mass loss.
- a difference between the first and second tissue mass impedance parameter values can be determined, and scaled by the scaling factor to allow a degree of tissue mass loss to be represented.
- lnd sf ⁇ R a - R ) (6) wherein: R t i is the first tissue mass impedance parameter value
- Ri2 is the second tissue mass impedance parameter value
- the scaling factor sf can be selected so that the value of the indicator is indicative of the change in LTM.
- the values for the scaling factor and constant may vary between different populations and body segments.
- the constant and scaling factor will typically be selected for the subject based on a reference population that is selected to take into account variations in impedance measurements that can arise due to variety of factors such as:
- Changes in the intracellular resistance, and hence changes in the tissue mass indicator may also depend on other factors in addition to the amount of lean tissue mass, such as changes in global fluid levels within the subject, the presence of oedema, or the like. Accordingly, to take these other factors into account, a second indicator can also be determined for example to reflect changes in fluid levels.
- one or more impedance values can optionally be used by the processing system 102, to determine one or more fluid level impedance parameter values.
- the nature of the fluid level impedance parameter value can vary, but in general this is at least partially indicative of the extracellular fluid levels, and more typically both the extracellular and intracellular fluid level. Accordingly, the fluid level impedance parameter values may be based on the impedance Ro at a zero frequency fo, although alternatively a may be used, as well as on the intracellular resistance R t .
- the fluid level impedance parameter value(s) can be used to determine a fluid level indicator.
- the fluid level indicator is in the form of a numerical value that can be used to determine the presence, absence or degree of a condition, such as oedema or lymphoedema, and which is typically based on the ratio of intracellular to extracellular fluid levels.
- the ratio IR is given by:
- the fluid level indicator is given by the numerical value of the ratio IR.
- the ratio can be compared to reference values determined from a reference population of healthy individuals, and in particular to the mean ratio value for the reference population. This can be used to determine deviation of the subject's ratio from that of healthy individuals in the reference population, which is in turn indicative of the presence, absence or degree of oedema.
- the fluid level indicator Indf can be determined using the equation (8):
- Indf is the fluid level indicator
- mean ratio for a reference population 3 ⁇ is three standard deviations for the reference population sf is a scaling factor
- the scaling factor is selected so that a threshold value indicative of at least one of a presence or absence of oedema is an integer value.
- a value such as "10" for the tissue indicator can be used to indicate the presence, absence or degree of oedema.
- the reference normal population is typically selected to take into account variations in impedance measurements that can arise due to variety of factors such as:
- changes in the ratio as determined from first and second fluid level impedance parameter values can be determined, and scaled by a scaling factor so that the indicator and the threshold can be a memorable value, such as an integer value, or the like. This can be achieved for example by calculating the fluid level indicators as follows: lndf ⁇ sfilR. - IR, ) (9) where: IR t is a first ratio
- IR2 is a second ratio
- the fluid indicator can be compared to a range derived from a normal population to determine if changes in the fluid levels within the subject are indicative of oedema, or are otherwise outside of an expected range.
- the tissue mass indicator, and optionally the fluid level indicator can be used to assess the lean tissue mass, and in particular, to determine if any changes in the tissue mass indicator are caused by changes in fluid levels in general, or are due to changes in the lean tissue mass.
- Figures 3C and 3D show an example of variations in the tissue mass indicator 300 and fluid level indicator 320, over time.
- the indicators are represented by absolute values of Rj and the ratio R/Ro, with a normal expected range of values derived from a study of healthy individuals being shown at 310 and 330, respectively.
- initial (first) readings are established to provide a baseline, with subsequent (second) readings being used to allow changes from this baseline to be monitored.
- the fluid level indicator 320 stays approximately level, and within the expected range for a normal population 330, thereby indicating that changes in the tissue mass indicator 300 are associated with a change in tissue mass, as opposed to more general changes in fluid levels, the presence of oedema, or the like. Accordingly, in this example, the rise in value of and hence tissue mass indicator 300, indicates a reduction in lean tissue mass.
- a reduction in lean tissue mass can be caused by a range of factors, such as malnutrition, a lack of exercise, or the like, depending on the scenario. Accordingly, in this example, treatment is administered, leading to a subsequent reduction in the value of Rj, and hence the lean tissue mass indicator 300. Again, the fluid level indicator 320 remains substantially unchanged, and within the normal range 330, thereby indicating that the reduction in tissue mass indicator 300 is associated with an increase in tissue mass, and hence that treatment is successful.
- subject details are determined and provided to the processing system 102.
- the subject details will typically include information such as limb dominance, details of any medical interventions, as well as information regarding the subject such as the subject's age, weight, height, sex, ethnicity or the like.
- the subject details can be used in selecting a suitable reference normal population, as well as for generating reports, as will be described in more detail below.
- the subject details may be supplied to the processing system 102 via appropriate input means, such as the I/O device 105.
- appropriate input means such as the I/O device 105.
- the information is input a single time and stored in an appropriate database, or the like, which may be connected as a peripheral device 104 via the external interface 103.
- the database can include subject data representing the subject details, together with information regarding previous tissue mass indicators, baseline impedance measurements recorded for the subject, or the like.
- the operator can use the processing system 102 to select a search database option allowing the subject details to be retrieved.
- a search database option allowing the subject details to be retrieved.
- This is typically performed on the basis of a subject identifier, such as a unique number assigned to the individual upon admission to a medical institution, or may alternatively be performed on the basis of name or the like.
- a database is generally in the form of an HL7 compliant remote database, although any suitable database may be used.
- the subject can be provided with a wristband or other device, which includes coded data indicative of the subject identifier.
- the measuring device 100 can be coupled to a peripheral device 104, such as a barcode or FID (Radio Frequency Identification) reader allowing the subject identifier to be detected and provided to the processing system 102, which in turn allows the subject details to be retrieved from the database.
- the processing system 102 can then display an indication of the subject details retrieved from the database, allowing the operator to review these and confirm their accuracy before proceeding further.
- one or more body segments of interest are determined. This may be achieved in any one of a number of ways depending on the preferred implementation.
- the affected limb can be indicated through the use of appropriate input means, such as the I/O device 105.
- this information can be derived directly from the subject details, which may include an indication of an at risk body segment, or details of any medical interventions performed or injuries incurred, which are in turn indicative of the at risk body segment.
- an operator positions the electrodes on the subject S, and connects the leads 123, 124, 125, 126, to allow the impedance measurements to be performed.
- the general arrangement is to provide electrodes on the hand at the base of the knuckles and between the bony protuberances of the wrist, as shown in Figure 5A, and on the feet at the base of the toes and at the front of the ankle, as shown in Figure 5B.
- the configurations shown in Figures 5C and 5D allow the right arm 531 and the right leg 533 to be measured respectively, and it will be appreciated that equivalent arrangements can be used to. measure the impedance of the left leg and left arm.
- this configuration uses the theory of equal potentials, allowing the electrode positions to provide, reproducible results for impedance measurements.
- the electrode 1 15B could be placed anywhere along the left arm 532, since the whole arm is at an equal potential. This is advantageous as it greatly reduces the variations in measurements caused by poor placement of the electrodes by the operator. It also greatly reduces the number of electrodes required to perform segmental body measurements, as well as allowing the limited connections shown to be used to measure each limb separately.
- any suitable electrode and lead arrangement may be used.
- any suitable segment of the subject can be measured, such as any large muscle group, including but not limited to the subject's back, calf, thigh, or the like.
- the electrode arrangement shown in Figure 5E can be used to measure the lean tissue mass in a subject's calf 540.
- the impedance of the at risk body segments are measured. This is achieved by applying one or more current signals to the subject and then measuring the corresponding voltages induced across the subject S. It will be appreciated that in practice the signal generators 1 17A, 1 17B, and the sensors 1 18 A, 1 18B, return signals to the processing system 102 indicative of the applied current and the measured voltage, allowing impedances to be determined.
- tissue mass and optionally fluid level impedance parameter values for each of the at risk body segments can be determined as described above.
- the tissue mass and fluid level impedance parameter values are typically indicative of the intracellular and extracellular resistances, and are therefore determined using impedance measurements made at one or more frequencies.
- any required reference values are selected, such as values of the constants or scaling factors, normal expected ranges, or the like.
- the reference is typically derived from equivalent measurements made on a reference population that is relevant to the subject under study. Thus, the population is typically selected taking into account factors such as medical interventions performed, ethnicity, sex, height, weight, limb dominance, the affected limb, or the like. Therefore if the test subject is female, with the at risk body segment being a dominant leg, then the reference values are drawn from a reference population database for the dominant leg of female subjects.
- the processing system 102 typically accesses reference populations stored in the database, or the like. This may be performed automatically by the processing system 102 using the subject details.
- the database may include a look-up table that specifies the normal population that should be used given a particular set of subject details. Alternatively selection may be achieved in accordance with predetermined rules that can be derived using heuristic algorithms based on selections made by medically qualified operators during previous procedures. Alternatively, this may be achieved under control of the operator, depending on the preferred implementation.
- the processing system 102 can be used to retrieve a reference from a central repository, for example via an appropriate server arrangement. In one example, this may be performed on a pay per use basis.
- predetermined standard reference values may be used. However it will be appreciated that different values can be used as appropriate and that these values are for illustration only.
- the reference value may be a baseline value previously measured for the test subject.
- the at risk body segment can be measured shortly after the injury and before a major loss in lean tissue mass has occurred. Changes in the measured values can then be used to accurately track changes in lean tissue mass over time.
- a tissue mass indicator can be determined at step 460, for example using equation (5) or (6) above. As described above, this is typically achieved by scaling the intracellular impedance value so that the resulting indicator represents a lean tissue mass, or alternatively comparing the intracellular impedance to a baseline, so that the tissue mass indicator represents a relative change in lean tissue mass.
- a fluid level indicator can also optionally be determined, for example using the ratio determined from equation (8) above.
- Representations of the tissue mass indicator and optionally, fluid level indicator can then be displayed at step 470, if required, thereby allowing a healthcare professional, or other suitable individual to make an assessment of the subject's lean tissue mass. This can be achieved using graphs similar to those shown above in Figures 3C and 3D. However, alternative representations for the indicators can be used, as will now be described with reference to Figures 6A and 6B.
- the representation is in the form of a linear indicator 600, having an associated scale 601 and a pointer 602.
- the position of the pointer 602 relative to the scale 601 is indicative of the indicator value.
- the indicator representation also includes a baseline indicator 610 representing the baseline reading for the subject, which is set to a value of "0" on the scale 601.
- the upper and lower thresholds are set to be a predetermined range from the baseline indicator representing a clinically relevant lean tissue mass change. This may therefore represent a change in lean tissue mass which warrants further intervention.
- the range thresholds are positioned at "-10" and "+10" on the scale 601 respectively, although this is not essential.
- the lower and upper thresholds 61 1 , 612 define a normal range 620, an investigation range 621 , and an intervention range 622.
- the ranges can be indicated through the use of background colours on the linear indicator, so that for example, the normal range 620 is shaded green, whilst the intervention ranges 621 , can be unshaded or shaded red.
- This allows an operator to rapidly evaluate the positioning of the pointer 602 within the ranges, allowing for fast and accurate diagnosis of medically relevant tissue mass loss.
- this is not essential, and alternatively, an absolute value of tissue mass may be displayed, depending on the preferred implementation.
- the linear indicator extends up to a value of "20" as this is able to accommodate the determined value of 16.6.
- the linear indicator can be extended to any value required to accommodate the determined indicator value.
- the linear indicator 600 may include discontinuities, allowing the scale to be extended to higher values. An example of this is shown in Figure 6C, in which a discontinuity 605 is used to separate the linear indicator 600 into two portions 600A, 600B.
- the linear indicator portion 600A extends from “-10" to “+20”, whilst the second linear indicator portion 600B extends from “+70” to “+90”, thereby allowing an indicator value of "80” is to be displayed by appropriate positioning of the pointer 602 in the indicator portion 605 B.
- linear indicator 600 Whilst a linear indicator 600 is preferred as this easily demonstrates to the operator the potential degree of severity of any tissue mass loss, this is not essential, and alternatively the scale may be modified, particularly if an outlier indicator value is determined.
- the linear indicator could include logarithmic scaling, or the like, over all or part of its length, to allow the determined indicator value to be displayed.
- the representation does not include a mean 610 or lower or upper thresholds 61 1, 612.
- the indicator value may be an absolute value calculated using equation (5) using reference values from a reference population.
- the thresholds 61 1 , 612, and hence the specific ranges 620, 621, 622, are excluded from the representation, highlighting to the operator that the scaled subject parameter value is indicative but not definitive of the subject's oedema status.
- the leads were arranged using the standard tetrapolar arrangement to determine total body (TB) impedance.
- TB total body impedance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Signal Processing (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Power Engineering (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012212386A AU2012212386B2 (en) | 2011-02-03 | 2012-01-31 | Tissue mass indicator determination |
JP2013552062A JP5970476B2 (en) | 2011-02-03 | 2012-01-31 | Determination of organizational quantity indicators |
US13/983,271 US20140031713A1 (en) | 2011-02-03 | 2012-01-31 | Tissue mass indicator determination |
EP12741653.5A EP2670301A4 (en) | 2011-02-03 | 2012-01-31 | Tissue mass indicator determination |
CA2863041A CA2863041A1 (en) | 2011-02-03 | 2012-01-31 | Tissue mass indicator determination |
US15/146,704 US20160317063A1 (en) | 2011-02-03 | 2016-05-04 | Tissue mass indicator determination |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011900340 | 2011-02-03 | ||
AU2011900340A AU2011900340A0 (en) | 2011-02-03 | Tissue mass indicator determination |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/983,271 A-371-Of-International US20140031713A1 (en) | 2011-02-03 | 2012-01-31 | Tissue mass indicator determination |
US15/146,704 Continuation US20160317063A1 (en) | 2011-02-03 | 2016-05-04 | Tissue mass indicator determination |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012103576A1 true WO2012103576A1 (en) | 2012-08-09 |
Family
ID=46602001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2012/000075 WO2012103576A1 (en) | 2011-02-03 | 2012-01-31 | Tissue mass indicator determination |
Country Status (6)
Country | Link |
---|---|
US (2) | US20140031713A1 (en) |
EP (1) | EP2670301A4 (en) |
JP (1) | JP5970476B2 (en) |
AU (1) | AU2012212386B2 (en) |
CA (1) | CA2863041A1 (en) |
WO (1) | WO2012103576A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016057461A1 (en) * | 2014-10-07 | 2016-04-14 | Cardiac Pacemakers, Inc. | Calibrating intrathoracic impedance for absolute lung fluid measurement |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9581627B2 (en) * | 2012-05-21 | 2017-02-28 | General Electric Company | Method and system for tomographic imaging |
TWI504379B (en) * | 2013-05-06 | 2015-10-21 | Tatung Co | Bioelectrical impedance measurement method |
US10357180B2 (en) * | 2014-01-16 | 2019-07-23 | D.T.R. Dermal Therapy Research Inc. | Health monitoring system |
US10786176B2 (en) * | 2014-03-07 | 2020-09-29 | School Juridical Person Kitasato Institute | Fat thickness estimating device, fat thickness estimating system, fat thickness measuring method, and program |
US10653333B2 (en) * | 2014-11-13 | 2020-05-19 | Ori Diagnostic Instruments, LLC | Systems and methods for high frequency impedance spectroscopy detection of daily changes of dielectric properties of the human body to measure body composition and hydration status |
US10004408B2 (en) | 2014-12-03 | 2018-06-26 | Rethink Medical, Inc. | Methods and systems for detecting physiology for monitoring cardiac health |
US11395628B2 (en) * | 2017-02-16 | 2022-07-26 | Samsung Electronics Co., Ltd. | Method of providing service based on biometric information and wearable electronic device |
JP2019208843A (en) * | 2018-06-04 | 2019-12-12 | ラピスセミコンダクタ株式会社 | Semiconductor device, measurement system, and measurement method |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449000A (en) | 1988-05-24 | 1995-09-12 | Abc Development | System for body impedance data acquisition utilizing segmental impedance & multiple frequency impedance |
EP0865763A2 (en) * | 1997-03-06 | 1998-09-23 | Nte, S.A. | Apparatus for measuring volumes and global and segmental corporal composition in human beings |
JP2000139867A (en) | 1998-11-10 | 2000-05-23 | Sekisui Chem Co Ltd | Body composition estimation method, body composition estimation apparatus and recording medium recording body composition estimation program |
WO2000079255A1 (en) | 1999-06-22 | 2000-12-28 | The University Of Queensland | A method and device for measuring tissue oedema |
US6208890B1 (en) * | 1998-03-03 | 2001-03-27 | Seb, S.A. | Device and method for measuring the composition of the body |
EP1177760A1 (en) * | 2000-08-01 | 2002-02-06 | Tanita Corporation | A body water amount condition judging apparatus by multi-frequency bioelectric impedance measurement |
US20040171963A1 (en) * | 2003-02-28 | 2004-09-02 | Tanita Corporation | Body composition estimation method and body composition measuring apparatus |
WO2005122888A1 (en) | 2004-06-18 | 2005-12-29 | The University Of Queensland | Oedema detection |
WO2008138602A1 (en) | 2007-05-16 | 2008-11-20 | Olympus Winter & Ibe Gmbh | Laparoscopy port valve |
WO2009059351A1 (en) | 2007-11-05 | 2009-05-14 | Impedimed Limited | Impedance determination |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1014899A (en) * | 1996-07-05 | 1998-01-20 | Sekisui Chem Co Ltd | Method and device for presumption of body composition |
JP3819637B2 (en) * | 1998-09-08 | 2006-09-13 | 積水化学工業株式会社 | Body composition estimation device |
AU2008251033B2 (en) * | 2007-05-14 | 2013-11-21 | Impedimed Limited | Indicator |
-
2012
- 2012-01-31 AU AU2012212386A patent/AU2012212386B2/en active Active
- 2012-01-31 JP JP2013552062A patent/JP5970476B2/en active Active
- 2012-01-31 EP EP12741653.5A patent/EP2670301A4/en not_active Ceased
- 2012-01-31 US US13/983,271 patent/US20140031713A1/en not_active Abandoned
- 2012-01-31 WO PCT/AU2012/000075 patent/WO2012103576A1/en active Application Filing
- 2012-01-31 CA CA2863041A patent/CA2863041A1/en not_active Abandoned
-
2016
- 2016-05-04 US US15/146,704 patent/US20160317063A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449000A (en) | 1988-05-24 | 1995-09-12 | Abc Development | System for body impedance data acquisition utilizing segmental impedance & multiple frequency impedance |
EP0865763A2 (en) * | 1997-03-06 | 1998-09-23 | Nte, S.A. | Apparatus for measuring volumes and global and segmental corporal composition in human beings |
US6208890B1 (en) * | 1998-03-03 | 2001-03-27 | Seb, S.A. | Device and method for measuring the composition of the body |
JP2000139867A (en) | 1998-11-10 | 2000-05-23 | Sekisui Chem Co Ltd | Body composition estimation method, body composition estimation apparatus and recording medium recording body composition estimation program |
WO2000079255A1 (en) | 1999-06-22 | 2000-12-28 | The University Of Queensland | A method and device for measuring tissue oedema |
EP1177760A1 (en) * | 2000-08-01 | 2002-02-06 | Tanita Corporation | A body water amount condition judging apparatus by multi-frequency bioelectric impedance measurement |
US20040171963A1 (en) * | 2003-02-28 | 2004-09-02 | Tanita Corporation | Body composition estimation method and body composition measuring apparatus |
WO2005122888A1 (en) | 2004-06-18 | 2005-12-29 | The University Of Queensland | Oedema detection |
WO2008138602A1 (en) | 2007-05-16 | 2008-11-20 | Olympus Winter & Ibe Gmbh | Laparoscopy port valve |
WO2009059351A1 (en) | 2007-11-05 | 2009-05-14 | Impedimed Limited | Impedance determination |
Non-Patent Citations (1)
Title |
---|
See also references of EP2670301A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016057461A1 (en) * | 2014-10-07 | 2016-04-14 | Cardiac Pacemakers, Inc. | Calibrating intrathoracic impedance for absolute lung fluid measurement |
US11179055B2 (en) | 2014-10-07 | 2021-11-23 | Cardiac Pacemakers, Inc. | Calibrating intrathoracic impedance for absolute lung fluid measurement |
Also Published As
Publication number | Publication date |
---|---|
JP2014504527A (en) | 2014-02-24 |
US20160317063A1 (en) | 2016-11-03 |
AU2012212386A1 (en) | 2013-04-04 |
US20140031713A1 (en) | 2014-01-30 |
CA2863041A1 (en) | 2012-08-09 |
EP2670301A1 (en) | 2013-12-11 |
EP2670301A4 (en) | 2014-07-02 |
JP5970476B2 (en) | 2016-08-17 |
AU2012212386B2 (en) | 2014-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210401320A1 (en) | Indicator | |
US11612332B2 (en) | Hydration status monitoring | |
AU2012212386B2 (en) | Tissue mass indicator determination | |
AU2010312305B2 (en) | Fluid level indicator determination | |
US9504406B2 (en) | Measurement apparatus | |
EP3322335B1 (en) | Fluid level determination | |
AU2011274290B2 (en) | Tissue indicator determination | |
AU2014202075B2 (en) | Fluid level indicator determination | |
AU2014200697B2 (en) | Indicator | |
AU2006301927B2 (en) | Hydration status monitoring |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12741653 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012212386 Country of ref document: AU Date of ref document: 20120131 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013552062 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012741653 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13983271 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2863041 Country of ref document: CA |